Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05681884 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Faricimab in Patients With NPDR
A Phase 2 study of Non-Proliferative Diabetic Retinopathy, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 16
- Study locations
NCT05681884 is a Phase 2 study of Non-Proliferative Diabetic Retinopathy that has completed, run by Greater Houston Retina Research. The registered enrollment target is 179 participants, below the 305-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (41% lower). The trial reports 16 study locations across 8 states.
The verdict
NCT05681884, a Phase 2 study of Non-Proliferative Diabetic Retinopathy, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
Conditions Studied
Interventions
- DRUG Faricimab
Study Locations (16)
Texas
- Austin Retina Associates - Austin
- Retina Consultants of Texas - Beaumont
- Retina Consultants of Texas - Bellaire
- Retina Consultants of Texas - Katy
- Retina Consultants of Texas - San Antonio
- Retina Consultants of Texas - The Woodlands
California
- California Retina Consultants - Bakersfield
- Retinal Consultants Medical Group - Modesto
Florida
- Florida Retina Institute - Orlando
- Retina Group of Florida - Sarasota
South Carolina
- Charleston Neuroscience Institute - Ladson
- Palmetto Retina Center - West Columbia
Minnesota
- Retina Consultants of Minnesota St. Louis Park - Saint Louis Park
Mississippi
- Mississippi Retina Associates - Jackson
New York
- Long Island Vitreoretinal Consultants - Westbury
North Carolina
- North Carolina Retina Associates - Wake Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2026-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05681884
The ClinicalTrials.gov registry entry for NCT05681884 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 4 other Non-Proliferative Diabetic Retinopathy trials with a reported enrollment target (41% lower). The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which Faricimab is the first listed.
NCT05681884 reports 16 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05681884 about?
NCT05681884 is a clinical study titled "Safety and Efficacy of Faricimab in Patients With NPDR". The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
What is the current status of trial NCT05681884?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2023-05-16. Estimated completion is 2026-02-26.
What conditions does trial NCT05681884 study?
This clinical trial studies the following conditions: Non-Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT05681884?
The interventions under investigation include: Faricimab (DRUG).
Who is sponsoring clinical trial NCT05681884?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05681884 being conducted?
This trial has 16 study locations across California, Florida, Minnesota, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
RECRUITING · Phase 3
-
Diabetes Visual Function Supplement Study
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.